Phase 3 Study of ALXN1850 in Pediatric Participants With HPP Previously Treated With Asfotase Alfa

NCT06079372 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

43

Enrollment

INDUSTRY

Sponsor class

Conditions

Hypophosphatasia

Interventions

DRUG: ALXN1850
DRUG: asfotase alfa

Sponsor

Alexion Pharmaceuticals, Inc.